IDNA Genomics Public Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-2.24	-2.52	-1.34
Depreciation & Amortization	0.32	0.29	0.24
Loss (Gain) From Sale of Assets	-	-	-0.09
Asset Writedown & Restructuring Costs	1.1	1.34	-
Other Operating Activities	-1.03	-0.3	0.14
Change in Accounts Receivable	0.03	-0.12	-0.02
Change in Inventory	-0.04	-0.05	-0.05
Change in Accounts Payable	1.62	-1.15	1.12
Operating Cash Flow	-0.25	-2.52	-0.01
Operating Cash Flow Growth	-	-	-
Capital Expenditures	-0	-0.01	-0
Divestitures	-	2	-
Sale (Purchase) of Intangibles	-	-0.16	-0.7
Investment in Securities	-	-0.01	-0.02
Investing Cash Flow	-0	1.82	-0.72
Long-Term Debt Issued	0.5	-	1.56
Long-Term Debt Repaid	-0.4	-0.12	-0.75
Net Debt Issued (Repaid)	0.1	-0.12	0.81
Other Financing Activities	-0.2	-0.15	-0.13
Financing Cash Flow	-0.09	-0.26	0.68
Net Cash Flow	-0.34	-0.96	-0.05
Free Cash Flow	-0.25	-2.53	-0.01
Free Cash Flow Growth	-	-	-
Free Cash Flow Margin	-50.83%	-528.51%	-2.62%
Free Cash Flow Per Share	-0.09	-0.92	-0.01
Levered Free Cash Flow	-0.24	-2.21	-
Unlevered Free Cash Flow	-0.12	-2.12	-
Cash Interest Paid	-	0.15	0.13
Cash Income Tax Paid	-	0.01	-
Change in Working Capital	1.61	-1.32	1.05